Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMB-07 in aggressive B-cell non-Hodgkin lymphoma
CTR20254500Phase 2Active
- Sponsor
- EpimAb Biotherapeutics
- Start
- Feb 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of EMB-07 in B-cell non-Hodgkin lymphoma (B-NHL), diffuse large B-cell lymphoma (DLBCL), double hit lymphoma (DHL), sponsored by EpimAb Biotherapeutics. Started Feb 2026; status: active.
02
Drugs
EMB-07
03
Conditions
B-cell non-Hodgkin lymphoma (B-NHL)diffuse large B-cell lymphoma (DLBCL)double hit lymphoma (DHL)
Beyond the preview
Go deeper on CTR20254500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254500.